Filing Flows › Regeneron Pharmaceuticals (REGN) › Collaboration revenue revenue
Regeneron Pharmaceuticals (REGN) Collaboration revenue revenue by quarter
Regeneron Pharmaceuticals' Collaboration revenue revenue was $3.0B in Q3 2026 (third quarter 2026), +22% from Q2 2026. Over the last 7 quarters it ranged from $1.5B (Q1 2025) to $3.0B (Q3 2026).
| Quarter | Collaboration revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $3.0B | +22% | +52% |
| Q2 2026 | $2.5B | +29% | +32% |
| Q1 2026 | $1.9B | -4% | +24% |
| Q4 2025 | $2.0B | +0.1% | — |
| Q3 2025 | $2.0B | +6% | — |
| Q2 2025 | $1.9B | +22% | — |
| Q1 2025 | $1.5B | — | — |
Q3 2026 at a glance
Regeneron Pharmaceuticals, Q3 2026: revenue $5.1B (+36% year over year), operating margin 40.0%, net earnings $1.9B, operating cash flow $1.8B. The chart follows the revenue to costs, profit and cash.
Questions
What is Regeneron Pharmaceuticals' Collaboration revenue revenue?
Regeneron Pharmaceuticals' Collaboration revenue revenue was $3.0B in Q3 2026 (third quarter 2026), +22% from Q2 2026.
How has Regeneron Pharmaceuticals' Collaboration revenue revenue changed?
Over the last 7 quarters it ranged from $1.5B (Q1 2025) to $3.0B (Q3 2026).
Q3 2026 results → · How Regeneron Pharmaceuticals makes money →